Beta Glucan and Lyme Disease (lD)

Preview this chapter:

Beta Glucan and Lyme Disease (lD), Page 1 of 1

< Previous page | Next page > /docserver/preview/fulltext/9789815039238/chapter-12-1.gif

<div&gt;Lyme disease (LD) is an insect-borne infectious disease caused by&lt;/div&gt;<div&gt;spirochetes-spiral shaped-flexible bacteria titled as Borrelia burgdorferi, has been&lt;/div&gt;<div&gt;rapidly growing in United States, Europe, and Asia. During Lyme disease, Borrelia&lt;/div&gt;<div&gt;burgdorferi causes the release of pro-inflammatory type cytokines such as interleukin&lt;/div&gt;<div&gt;(IL-1), and T-helper cell-derived cytokines stimulating inflammation. Lyme disease&lt;/div&gt;<div&gt;causes a wide scale of disorders on the human body i.e. skin, heart. It builds a broad&lt;/div&gt;<div&gt;scale of problems such as arthritic symptoms at joints, nervous system problems,</div&gt;<div&gt;bacterial infection, flu-like symptoms [1]. It creates a systemic problem for the host,</div&gt;<div&gt;which can include, and Experimental studies showed that treatment with antibiotics&lt;/div&gt;<div&gt;with 3-6 beta-glucan creates a synergistic effect on bacterial and viral infections due to&lt;/div&gt;<div&gt;Lyme-Multiple Systemic Infectious Disease Syndrome (MSIDS) [2]. In this minireview,</div&gt;<div&gt;the therapeutical effect of beta glucan on Lyme disease is examined in detail. </div&gt;